Literature DB >> 31698356

Consensus Statement by an Expert Panel on the Diagnosis and Management of Iron Deficiency Anemia in the Gulf Cooperation Council Countries.

Aamer Aleem1, Faisal Alsayegh2, Satish Keshav3, Abdulrahman Alfadda4, Ahmad Awad Alfadhli5, Abdulrahman Al-Jebreen6, Fawaz Al-Kasim7, Ali Almuhaini8, Hazzaa Al-Zahrani9, Faisal Batwa10, Srdjan Denic11, Ahmad Jazzar12, Tarek Owaidah13, Mohamad Qari14, Yousef Qari15, Mazen Taha16.   

Abstract

BACKGROUND: Iron deficiency (ID) and ID anemia (IDA) are common in the member states of the Gulf Cooperation Council (GCC). The unique genetic and lifestyle factors of the patient population in the region have necessitated the development of recommendations to help educate health-care professionals on appropriate diagnosis and management of ID/IDA.
METHODS: A panel of regional experts, including gastroenterologists and hematologists with expertise in the treatment of IDA, was convened to develop regional practice recommendations for ID/IDA. After reviewing the regional and international literature, the expert panel developed consensus recommendations for screening, diagnosis, and treatment of patients with IDA in the GCC region.
RESULTS: The recommendations proposed were customized to the patient population keeping in view the increasingly recognized burden of coeliac disease, high fertility and obesity rates, high prevalence of alpha- and beta-thalassemia traits, and poor tolerance and low treatment compliance with oral iron therapy.
CONCLUSIONS: This consensus statement proposes recommendations for screening, diagnosis, and treatment of IDA in the GCC region.
© 2019 The Author(s) Published by S. Karger AG, Basel.

Entities:  

Keywords:  Diagnosis; Gulf Cooperation Council; Iron deficiency anemia; Management

Mesh:

Year:  2019        PMID: 31698356      PMCID: PMC7445696          DOI: 10.1159/000503707

Source DB:  PubMed          Journal:  Med Princ Pract        ISSN: 1011-7571            Impact factor:   1.927


  30 in total

Review 1.  Celiac disease in Middle Eastern and North African countries: a new burden?

Authors:  Kassem Barada; Abbas Bitar; Mohamad Abdul-Razak Mokadem; Jana Ghazi Hashash; Peter Green
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

2.  Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations.

Authors:  A E Mast; M A Blinder; A M Gronowski; C Chumley; M G Scott
Journal:  Clin Chem       Date:  1998-01       Impact factor: 8.327

3.  European consensus on the diagnosis and management of iron deficiency and anaemia in inflammatory bowel diseases.

Authors:  Axel U Dignass; Christoph Gasche; Dominik Bettenworth; Gunnar Birgegård; Silvio Danese; Javier P Gisbert; Fernando Gomollon; Tariq Iqbal; Konstantinos Katsanos; Ioannis Koutroubakis; Fernando Magro; Guillaume Savoye; Jürgen Stein; Stephan Vavricka
Journal:  J Crohns Colitis       Date:  2014-12-03       Impact factor: 9.071

4.  The health care cost of intravenous iron treatment in IBD patients depends on the economic evaluation perspective.

Authors:  Palle Bager; Jens F Dahlerup
Journal:  J Crohns Colitis       Date:  2010-02-16       Impact factor: 9.071

5.  Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women.

Authors:  Diego Moretti; Jeroen S Goede; Christophe Zeder; Markus Jiskra; Vaiya Chatzinakou; Harold Tjalsma; Alida Melse-Boonstra; Gary Brittenham; Dorine W Swinkels; Michael B Zimmermann
Journal:  Blood       Date:  2015-08-19       Impact factor: 22.113

6.  A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia.

Authors:  Jane E Onken; David B Bregman; Robert A Harrington; David Morris; Peter Acs; Bruce Akright; Charles Barish; Birbal S Bhaskar; Gioi N Smith-Nguyen; Angelia Butcher; Todd A Koch; Lawrence T Goodnough
Journal:  Transfusion       Date:  2013-06-17       Impact factor: 3.157

Review 7.  Anemia after bariatric surgery: more than just iron deficiency.

Authors:  Annette von Drygalski; Deborah A Andris
Journal:  Nutr Clin Pract       Date:  2009 Apr-May       Impact factor: 3.080

8.  A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial.

Authors:  Stefanie Kulnigg; Simeon Stoinov; Vladimir Simanenkov; Larisa V Dudar; Waldemar Karnafel; Luis Chaires Garcia; Alicia M Sambuelli; Geert D'Haens; Christoph Gasche
Journal:  Am J Gastroenterol       Date:  2008-03-26       Impact factor: 10.864

9.  Prevalence of anemia and associated factors in child bearing age women in riyadh, saudi arabia.

Authors:  Aljohara M Alquaiz; Ashry Gad Mohamed; Tawfik A M Khoja; Abdullah Alsharif; Shaffi Ahamed Shaikh; Hamad Al Mane; Abdallah Aldiris; Ambreen Kazi; Durdana Hammad
Journal:  J Nutr Metab       Date:  2013-09-24

10.  A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).

Authors:  Walter Reinisch; Michael Staun; Rakesh K Tandon; Istvan Altorjay; Andrew V Thillainayagam; Cornelia Gratzer; Sandeep Nijhawan; Lars L Thomsen
Journal:  Am J Gastroenterol       Date:  2013-10-22       Impact factor: 10.864

View more
  2 in total

Review 1.  New Entity-Thalassemic Endocrine Disease: Major Beta-Thalassemia and Endocrine Involvement.

Authors:  Mara Carsote; Cristina Vasiliu; Alexandra Ioana Trandafir; Simona Elena Albu; Mihai-Cristian Dumitrascu; Adelina Popa; Claudia Mehedintu; Razvan-Cosmin Petca; Aida Petca; Florica Sandru
Journal:  Diagnostics (Basel)       Date:  2022-08-09

2.  Iron Deficiency Anemia as a Factor in Male Infertility: Awareness in Health College Students in the Jazan Region of Saudi Arabia.

Authors:  Mohammad S Akhter; Hassan A Hamali; Johar Iqbal; Abdullah A Mobarki; Hina Rashid; Gasim Dobie; Aymen M Madkhali; Bader Y H Arishi; Emad O O Ageeli; Osama S H Laghbi
Journal:  Int J Environ Res Public Health       Date:  2021-12-07       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.